{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Property of the Sanofi Group - strictly confidential', 'Page 132', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Appendix G NeuroQOL', 'Physical (fatigue and pain) and mental (cognitive function, anxiety, depression)', '\u00a92008-2013 David Cella and the PROMIS Health Organization on behalf of the National Institute for Neurological', 'Disorders and Stroke (NINDS). Used with permission.', 'English', 'Page 1 of 1', 'July 11, 2014', 'Property of the Sanofi Group - strictly confidential', 'Page 133', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Property of the Sanofi Group - strictly confidential', 'Page 134', 'VV-CLIN-0254406: 5.0']\n\n###\n\n", "completion": "END"}